Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

• Status: Completed
• Trial end date: 2016-12-20
• Target enrollment: 0
• Participant gender: All

Summary

The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Axitinib

Criteria

Inclusion Criteria:

• Locally advanced or metastatic HCC

• Failure of one prior antiangiogenic therapy including sorafenib, bevacizumab and brivanib.

• Child-Pugh Class A or B (score 7 only) disease.

Exclusion Criteria:

• Prior treatment of advanced HCC with more than one prior first-line systemic therapy.

• Any prior local therapy within 2 weeks of starting the study treatment.

• Presence of hepatic encephalopathy and/or clinically relevant ascites.

• Presence of main portal vein invasion by HCC.